96826-17-4

Usage

InChI:InChI=1/C18H20F2O2/c1-17(2,13-7-5-11(21)9-15(13)19)18(3,4)14-8-6-12(22)10-16(14)20/h5-10,21-22H,1-4H3

Upstream product

• 96826-32-3 2,3-bis(2-fluoro-4-methoxyphenyl)-2,3-dimethylbutane 
• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 
• 96826-25-4 2-(2-fluoro-4-methoxyphenyl)-2-isopropanol 

Downstream Products

• 127530-39-6 2,3-Bis(4-β-chloropropionyloxy-2-fluorophenyl)-2,3-dimethylbutane 
• 127530-38-5 2,3-Bis(4-acryloyloxy-2-fluorophenyl)-2,3-dimethylbutane 
• 127530-40-9 2,3-Bis(4-β-bromopropionyloxy-2-fluorophenyl)-2,3-dimethylbutane 

Relevant academic research and scientific papers

Derivatives of 1,1,2,2-tetramethyl-1,2-bis-(2-fluoro-4-hydroxyphenyl)-ethane

Antitumor compounds corresponding to the following formula: STR1 in which the substituents R1 and R2 may be the same or different and represent hydrogen, an aminocarbonyl group, a C1 -C6 alkylaminocarbonyl group, a di-C1 -C6 -alkylaminocarbonyl group, the group PO(OH)2, a C2 -C8 alkanoyl group, a C2 -C8 halogen alkanoyl group or a C3 -C8 alkenoyl group, a process for their preparation, and their use in treating oestrogen-receptor-positive-tumors as well as the prostate carcinoma.

Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydroxyphenyl)ethanes

The syntheses of symmetrically 2,2'-disubstituted derivatives of 1,1,2,2-tetramethyl-1,2bis(4-hydroxyphenyl)ethane (1) are and of 5,5'-, and 6,6'-disubstituted derivatives of 1,1,2,2-tetramethyl-1,2-bis(3-hydroxyphenyl)ethane (6) are described (1 and 6 are strong antiestrogens with mammary tumor inhibiting activity exhibiting only slight estrogenic properties): (2,2'-substituents) F (2), Cl (3), OCH3 (4), CH3 (5); (5,5'-substituents) Cl (7); (6,6'-substituents) F (8), Cl (9), OCH3 (10), CH3 (11). The synthesis of 1-11 was accomplished by reductive coupling of the corresponding 2-phenyl-2-propanols with TiCl3 and LiAlH4. The binding affinity of the compounds to the calf uterine estrogen receptor was measured relative to that of [3H]estradiol by a competitive binding assay. With the exception of 7 and 10 all other compounds showed relative binding affinity (RBA) values between 0.5 and 6.4% that of estradiol, 2 (RBA value 6.4), and 8 and 9 (4.0 and 3.5), exceeding those of the corresponding unsubstituted 1 and 6 (3.6 and 3.0). Compounds exhibiting RBA values of >2.5% were evaluated in the mouse uterine weight test. The substituted derivatives showed an increase in uterotrophic and a decrease in antiuterotrophic activity compared to 1 and 6. Compound 2 showed a strong, dose-dependent inhibition on the DMBA-induced hormone-dependent mammary tumor of the SD-rat, exceeding that of the parent compound 1. At a dose of 5 mg/kg per day, 2 reduced total tumor area by 47% and caused a complete remission in 74% of the tumors.